BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23494179)

  • 1. Clinical significance of annexin II expression in human non-small cell lung cancer.
    Jia JW; Li KL; Wu JX; Guo SL
    Tumour Biol; 2013 Jun; 34(3):1767-71. PubMed ID: 23494179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
    Ni SS; Zhang J; Zhao WL; Dong XC; Wang JL
    Tumour Biol; 2013 Jun; 34(3):1813-8. PubMed ID: 23475633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.
    Li H; Zhou RJ; Zhang GQ; Xu JP
    Tumour Biol; 2013 Jun; 34(3):1807-12. PubMed ID: 23471668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer.
    Zhang Q; Ye Z; Yang Q; He X; Wang H; Zhao Z
    World J Surg Oncol; 2012 Jun; 10():103. PubMed ID: 22681645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of annexin II expression in non-small cell lung cancer.
    Luo CH; Liu QQ; Zhang PF; Li MY; Chen ZC; Liu YF
    Clin Transl Oncol; 2013 Nov; 15(11):938-46. PubMed ID: 23529818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer.
    Xing R; Chen KB; Xuan Y; Feng C; Xue M; Zeng YC
    Surg Oncol; 2016 Sep; 25(3):147-51. PubMed ID: 27566015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.
    Wei LX; Zhou RS; Xu HF; Wang JY; Yuan MH
    Tumour Biol; 2013 Apr; 34(2):941-6. PubMed ID: 23264086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer.
    Xu CH; Sheng ZH; Hu HD; Hao KK; Wang QB; Yu LK
    Tumour Biol; 2014 Sep; 35(9):8673-8. PubMed ID: 24870591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
    Zhang Z; Guo Y
    Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Sam68 expression predicts poor prognosis in non-small cell lung cancer.
    Zhang Z; Xu Y; Sun N; Zhang M; Xie J; Jiang Z
    Clin Transl Oncol; 2014 Oct; 16(10):886-91. PubMed ID: 24522888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.
    Zhang H; Duan CJ; Chen W; Wang SQ; Zhang SK; Dong S; Cheng YD; Zhang CF
    Asian Pac J Cancer Prev; 2012; 13(5):2355-62. PubMed ID: 22901222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.
    Han KY; Gu X; Wang HR; Liu D; Lv FZ; Li JN
    Tumour Biol; 2013 Apr; 34(2):821-5. PubMed ID: 23229099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer.
    Ping W; Jiang WY; Chen WS; Sun W; Fu XN
    Asian Pac J Cancer Prev; 2013; 14(6):3613-8. PubMed ID: 23886154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).
    Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN
    Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
    Wei L; Sun JJ; Cui YC; Jiang SL; Wang XW; Lv LY; Xie L; Song XR
    Tumour Biol; 2016 Jul; 37(7):9979-87. PubMed ID: 26819207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated expression of CRYAB predicts unfavorable prognosis in non-small cell lung cancer.
    Qin H; Ni Y; Tong J; Zhao J; Zhou X; Cai W; Liang J; Yao X
    Med Oncol; 2014 Aug; 31(8):142. PubMed ID: 25048725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression.
    Wang X; Sun Q; Chen C; Yin R; Huang X; Wang X; Shi R; Xu L; Ren B
    Oncotarget; 2016 Feb; 7(7):8029-42. PubMed ID: 26771237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
    Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
    Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.